1. Academic Validation
  2. DAZAP2 acts as specifier of the p53 response to DNA damage

DAZAP2 acts as specifier of the p53 response to DNA damage

  • Nucleic Acids Res. 2021 Mar 18;49(5):2759-2776. doi: 10.1093/nar/gkab084.
Magdalena C Liebl 1 Jutta Moehlenbrink 1 Huong Becker 1 Günter Raddatz 2 Suhaib K Abdeen 3 Rami I Aqeilan 3 4 Frank Lyko 2 Thomas G Hofmann 1
Affiliations

Affiliations

  • 1 Institute of Toxicology, University Medical Center Mainz, Johannes Gutenberg University, Mainz, Germany.
  • 2 Division of Epigenetics, German Cancer Research Center (dkfz), Heidelberg, Germany.
  • 3 The Concern Foundation Laboratories, The Lautenberg Center for Immunology and Cancer Research, Department of Immunology and Cancer Research-IMRIC, Hebrew University-Hadassah Medical School, Jerusalem, Israel.
  • 4 Department of Cancer Biology and Genetics, Wexner Medical Center, The Ohio State University, Columbus, OH, USA.
Abstract

The DNA damage-responsive tumor suppressors p53 and HIPK2 are well established regulators of cell fate decision-making and regulate the cellular sensitivity to DNA-damaging drugs. Here, we identify Deleted in Azoospermia-associated protein 2 (DAZAP2), a small adaptor protein, as a novel regulator of HIPK2 and specifier of the DNA damage-induced p53 response. Knock-down or genetic deletion of DAZAP2 strongly potentiates Cancer cell chemosensitivity both in cells and in vivo using a mouse tumour xenograft model. In unstressed cells, DAZAP2 stimulates HIPK2 polyubiquitination and degradation through interplay with the ubiquitin Ligase SIAH1. Upon DNA damage, HIPK2 site-specifically phosphorylates DAZAP2, which terminates its HIPK2-degrading function and triggers its re-localization to the cell nucleus. Interestingly, nuclear DAZAP2 interacts with p53 and specifies target gene expression through modulating a defined subset of p53 target genes. Furthermore, our results suggest that DAZAP2 co-occupies p53 response elements to specify target gene expression. Collectively, our findings propose DAZAP2 as novel regulator of the DNA damage-induced p53 response that controls Cancer cell chemosensitivity.

Figures